Delisting riskPopularity #4,865
Alzamend Neuro (ALZN)
Develops AL001 and ALZN002 candidates for Alzheimer’s disease and psychiatric disorders.
$1.94
vs last close−0.00 (−0.26%)
In millions of USD, except per-share figures
| In millions | Q2 FY24Oct 2023 | Q3 FY24Jan 2024 | Q4 FY24Apr 2024 | Q1 FY25Jul 2024 | Q2 FY25Oct 2024 | Q3 FY25Jan 2025 | Q4 FY25Apr 2025 | Q1 FY26Jul 2025 | Q2 FY26Oct 2025 | Q3 FY26Jan 2026 | Q4 FY26Apr 2026 | Q1 FY27Jul 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3 | 3 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 3 | 3 | |
| Research & development | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 1 |
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 2 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −3 | −3 | −1 | −1 | −1 | −1 | −1 | −3 | −1 | −2 | −3 | −3 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −3 | −3 | −1 | −1 | −1 | −1 | −1 | −3 | −1 | −2 | −3 | −3 |
| Net income from continuing operations | −3 | −3 | −1 | −1 | −1 | −1 | −1 | −3 | −1 | −2 | −3 | −3 |
| Net income | −3 | −3 | −1 | −1 | −1 | −1 | −1 | −3 | −1 | −2 | −3 | −3 |
| EPS, basic | −$39.85 | −$33.97 | −$11.14 | −$11.42 | −$3.61 | −$1.70 | −$2.43 | −$1.28 | −$0.30 | −$0.58 | −$0.74 | −$0.68 |
| EPS, diluted | −$39.85 | −$33.97 | −$11.14 | −$11.42 | −$3.61 | −$1.70 | −$2.43 | −$1.28 | −$0.30 | −$0.58 | −$0.74 | −$0.68 |
| Weighted average shares, basic | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 3 | 4 | 3 | 4 |
| Weighted average shares, diluted | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 3 | 4 | 3 | 4 |
| EBITDA | −3 | −3 | −1 | −1 | −1 | −1 | −1 | −3 | −1 | −2 | −3 | −3 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −3 | −3 | −1 | −1 | −1 | −1 | −1 | −3 | −1 | −2 | −3 | −3 |